Likewise, elements of the SWI/SNF complex have been shown to be required for non-homologous end joining (NHEJ) activity of DSBs in human cancer cells, suggesting that the SWI/SNF complex could favor resistance to therapeutic agents that induce DNA damage in tumor cells [28]. The gene discussed is SMARCA1; the disease is neoplasm.